News
Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs.The company is set to capture 50% ...
While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...
Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...
Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...
Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...
Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC ...
Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...
Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.
7d
Barchart on MSNEli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell a Different StoryAt first glance, pharmaceutical giant Eli Lilly (LLY) may seem like an awfully risky wager. On Friday, LLY stock fell 2.47%, ...
The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...
In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results